Home › Trial NCT06196255
Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
- Trial IDNCT06196255
- StatusRecruiting
- PhasePhase 1/2
- Study typeInterventional
- SponsorXuzhou Medical University
- Enrollment20
- Start date2023-12-25
- ConditionsMultiple Myeloma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.